CLINICAL TRIALS PROFILE FOR SACUBITRIL AND VALSARTAN

All Clinical Trials for SACUBITRIL AND VALSARTAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01920711 ↗	Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction	Completed	Novartis Pharmaceuticals	Phase 3	2014-07-18	The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
NCT02554890 ↗	Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.	Completed	Novartis Pharmaceuticals	Phase 4	2016-04-29	The purpose of this study was to assess the effect of in-hospital initiation of sacubitril/valsartan (LCZ696) vs. enalapril on time averaged proportional change in NT-proBNP in patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF) and reduced ejection fraction (left ventricular ejection fraction (LVEF) ≤ 40%).
NCT02636283 ↗	Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease	Terminated	American Heart Association	Phase 2	2017-12-31	This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
NCT02636283 ↗	Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease	Terminated	University of Minnesota	Phase 2	2017-12-31	This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
NCT02636283 ↗	Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease	Terminated	University of Minnesota - Clinical and Translational Science Institute	Phase 2	2017-12-31	This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
NCT02682719 ↗	Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation	Active, not recruiting	Novartis Ireland Ltd	Phase 2	2015-12-16	Sacubitril-valsartan, an Angiotensin Receptor Blocker-Neprilysin Inhibitor (ARNI), currently marketed for the management of heart failure, has been shown to reduce cardiovascular morbidity and mortality in stage C heart failure with reduced ejection fraction. In stage C HFpEF, sacubitril-valsartan has also been shown to reduce left atrial volume index measured using echocardiography over a 9 month timeframe. The PARABLE study investigates the hypothesis that sacubitril-valsartan can provide benefits in terms of left atrial structure and function as well as left ventricular structure and function in asymptomatic (stage A/B HFpEF) patients. This is a prospective, randomised, double-blind, double-dummy, phase II study design. The patient population will have hypertension and/or diabetes together with preserved ejection fraction, elevated natriuretic peptide (NP) and abnormal left atrial volume index (LAVI, > 28 mL/m2).
NCT02682719 ↗	Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation	Active, not recruiting	The Heartbeat Trust	Phase 2	2015-12-16	Sacubitril-valsartan, an Angiotensin Receptor Blocker-Neprilysin Inhibitor (ARNI), currently marketed for the management of heart failure, has been shown to reduce cardiovascular morbidity and mortality in stage C heart failure with reduced ejection fraction. In stage C HFpEF, sacubitril-valsartan has also been shown to reduce left atrial volume index measured using echocardiography over a 9 month timeframe. The PARABLE study investigates the hypothesis that sacubitril-valsartan can provide benefits in terms of left atrial structure and function as well as left ventricular structure and function in asymptomatic (stage A/B HFpEF) patients. This is a prospective, randomised, double-blind, double-dummy, phase II study design. The patient population will have hypertension and/or diabetes together with preserved ejection fraction, elevated natriuretic peptide (NP) and abnormal left atrial volume index (LAVI, > 28 mL/m2).

Clinical Trial Conditions for SACUBITRIL AND VALSARTAN

Condition Name

Condition Name for SACUBITRIL AND VALSARTAN
Intervention	Trials
Heart Failure	32
Hypertension	8
Heart Failure With Preserved Ejection Fraction	7
Cardiotoxicity	3

Condition MeSH

Condition MeSH for SACUBITRIL AND VALSARTAN
Intervention	Trials
Heart Failure	60
Hypertension	7
Myocardial Infarction	6
Infarction	5

Clinical Trial Locations for SACUBITRIL AND VALSARTAN

Trials by Country

Trials by Country for SACUBITRIL AND VALSARTAN
Location	Trials
United States	267
Italy	53
Spain	50
Japan	47
China	36

Trials by US State

Trials by US State for SACUBITRIL AND VALSARTAN
Location	Trials
California	11
Massachusetts	10
Virginia	10
Tennessee	10
Minnesota	9

Clinical Trial Progress for SACUBITRIL AND VALSARTAN

Clinical Trial Phase

Clinical Trial Phase for SACUBITRIL AND VALSARTAN
Clinical Trial Phase	Trials
Phase 4	40
Phase 3	16
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for SACUBITRIL AND VALSARTAN
Clinical Trial Phase	Trials
Recruiting	37
Completed	21
Not yet recruiting	19

Clinical Trial Sponsors for SACUBITRIL AND VALSARTAN

Sponsor Name

Sponsor Name for SACUBITRIL AND VALSARTAN
Sponsor	Trials
Novartis Pharmaceuticals	22
Brigham and Women's Hospital	4
The Heartbeat Trust	3

Sponsor Type

Sponsor Type for SACUBITRIL AND VALSARTAN
Sponsor	Trials
Other	120
Industry	30
NIH	4